Landmark approval for new mode of action against migraines

18 May 2018

The first ever approval in a new and much-anticipated class of therapy, calcitonin gene-related peptide (CGRP) inhibitors, has been granted by the US Food and Drug Administration.

California’s Amgen (Nasdaq: AMGN) announced today that its migraine therapy Aimovig (erenumab-aooe), which is administered via once-monthly self-injections, was approved based on Phase II and III data which showed significant reductions in monthly migraine days and use of acute migraine medications compared to placebo.

The therapy is the result of a 2015 global collaboration with Switzerland’s Novartis (NOVN: VX) to develop and commercialize migraine and Alzheimer's therapies.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK